Quince Therapeutics shareholders approve reverse stock split and elect three directors

Quince Therapeutics, Inc.

Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.
Elected Class II directors Dirk Thye, David Lamond, and Luca Benatti to serve until 2027 annual meeting.
Ratified BDO USA as independent registered accounting firm for fiscal year ending Dec 31, 2024.
Advisory say-on-pay approved: 17,945,554 for, 429,833 against, 94,767 abstentions (14,090,117 broker non-votes).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.